GenSciences Raises $124 Million for New Drug Development
publication date: Mar 4, 2021
GenSciences, a commercial-stage Changchun drug company, has raised over $124 million in its series A and B rounds, the company announced. GenSci is a wholly owned subsidiary of Changchun High-Tech Industry, which was started as a construction company, but narrowed its focus to life science. Its portfolio includes genetically engineered pharmaceuticals, biological vaccines and modern traditional Chinese medicine. In November 2020, GenSci in-licensed China rights to ready-to-use subcutaneous depot formulations for a prostate cancer therapy from Taiwan's Foresee Pharma. More details....
Stock Symbol: (SHZ: 000661)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.